0000000000715240

AUTHOR

Kerstin Julia Schäfer

showing 2 related works from this author

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with…

2020

Oral drug absorption is a complex process depending on many factors, including the physicochemical properties of the drug, formulation characteristics and their interplay with gastrointestinal physiology and biology. Physiological-based pharmacokinetic (PBPK) models integrate all available information on gastro-intestinal system with drug and formulation data to predict oral drug absorption. The latter together with in vitro-in vivo extrapolation and other preclinical data on drug disposition can be used to predict plasma concentration-time profiles in silico. Despite recent successes of PBPK in many areas of drug development, an improvement in their utility for evaluating oral absorption i…

Data AnalysisPhysiologically based pharmacokinetic modellingDatabases FactualAdministration OralPharmaceutical Science02 engineering and technologyMachine learningcomputer.software_genreModels Biological030226 pharmacology & pharmacyBiopharmaceuticsPharmaceutical Sciences03 medical and health sciences0302 clinical medicineSoftwarePharmacokineticsHumansClinical Trials as Topicbusiness.industryCompound specificBiopharmaceuticsGeneral MedicineFarmaceutiska vetenskaper021001 nanoscience & nanotechnologyBioavailabilityIntestinal AbsorptionPharmaceutical PreparationsDrug developmentPerformance indicatorArtificial intelligence0210 nano-technologybusinesscomputerSoftwareForecastingBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopha…

2018

The ability to predict new chemical entity performance using in vivo animal models has been under investigation for more than two decades. Pharmaceutical companies use their own strategies to make decisions on the most appropriate formulation starting early in development. In this paper the biopharmaceutical decision trees available in four EFPIA partners (Bayer, Boehringer Ingelheim, Bristol Meyers Squibb and Janssen) were discussed by 7 companies of which 4 had no decision tree currently defined. The strengths, weaknesses and opportunities for improvement are discussed for each decision tree. Both pharmacokineticists and preformulation scientists at the drug discovery & development interf…

Chemistry PharmaceuticalDecision treePharmaceutical ScienceBiological Availability02 engineering and technology030226 pharmacology & pharmacyBiopharmaceutics03 medical and health sciences0302 clinical medicineDrug DevelopmentIn vivoNew chemical entityDrug DiscoveryAnimalsHumansBiological ProductsManagement scienceDrug discoveryDecision TreesGeneral Medicine021001 nanoscience & nanotechnologyClinical trialIdentification (information)BiopharmaceuticalDrug development0210 nano-technologyBiotechnologyEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct